China Health Resource, through its wholly owned subsidiary Suining Yinfa, has completed a key scientific research project in collaboration with Chengdu Chinese Traditional Medicine & Science University and the Sichuan Chinese Medicine Research Institute.

This research addresses innovative products in the areas of cough, diabetes, headaches, and chronic fatigue OTC and TCM pharmaceuticals. "We expect to announce some of the products addressed by this research regarding clinical trials and other commercial phases of development next," said Jiayin Wang, chairman and CEO of CHRI.

Traditional Chinese medicine (TCM) pharmaceutical products, along with western pharmaceuticals, are essential to the central healthcare system in China. The industry has been and is expected to continue growing significantly. In recent years in western countries such as the U.S., awareness of the benefits of TCM products has become increasingly attractive.

The research project, which was formally started in April 2008, covered research related to DAR, Frictillaria, Berberine and other TCM herbs considered by company and industry experts to address major healthcare problems. These studies use DAR as a key ingredient in combination with other natural herbs. DAR is known for its properties to treat pain, swelling and pustule.

The research was supported by government grants and the intellectual property and commercial rights belongs to the company. The project incurred total expense of 37.5 million RMB. The research by Yingfa, Chengdu TCM University and the Medicine Institute had received Governmental Research Support Grant of 4.2 million RMB.